Unless otherwise defined, the abbreviations and definitions used in the announcements dated 6, 10, 14 and 28 August 2020, 5, and 14 October 2020 as well as 2 November 2020 (“Announcements”) shall apply herein.

We refer to the Announcements in relation to the above.

The Board of Directors of HWGB is pleased to announce that following the approval from U.S. Food and Drug Administration being obtained by EBI to commence its Phase IV clinical research study on the effectiveness of poliomyelitis virus vaccine for prevention of COVID-19, HWGB Biotech shall release the Investment Sum less the non-refundable deposit of USD100,000.00 to EBI pursuant to the JV Agreement.

This announcement is dated 2 November 2020.